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SPIN TRAPPING COMPOUNDS

that cells which have a buildup of oxidized protein are less
functional and less able to maintain the speci?ed role of

CROSS-REFERENCE TO RELATED
APPLICATIONS

those cells in that particular area of the central nervous

This is a continuation of application Ser. No. 08/365548.
?led Dec. 28. 1994. now US. Pat. No. 5.578.617. which is
a divisional of application Ser. No. 08/027559. ?led Mar. 5.
1993. now US. Pat. No. 5.405.874. which is a continuation

investigators. there are no reports of substantial investiga
tions in which alterations in the oxidized protein burden of
the central nervous system was manipulated and correlated

of application Ser. No. 071589.177. ?led Sep. 27. 1990. now
abandoned. which is a continuation-in-part of application

system. While this hypothesis has been suggested by several

with a functional outcome on the part of the animal. Such an
10

approach. if truly associated with brain dysfunction. would
provide a basis for reversing the age related neuronal de?cit
of cells that are still viable. Thus. such an approach is
targeted at cells which are marginally functional but still
viable.

Ser. No. 07/422.651. ?led Oct. 17. 1989. now US. Pat. No.

5.025.032.
BACKGROUND OF THE INVENTION

It is therefore the object of the present invention to
provide composition and methods for the use in preventing

The present invention is a method and compositions

or reversing age related functional de?cits.

containing spin trapping agents for the treatment of age
related dysfunctions and other conditions arising from oxi

It is further the object of the present invention to provide

dative damage.

composition and methods for use thereof which are useful in

Age related changes in central nervous system function 20 preventing and reversing cognitive de?cits associated with
have generally been associated with the loss of cells. a
infection or in?ammation.
widening of lateral ventricles and de?cits in short term
It is another object of the present invention to provide
memory. The precise mechanisms of functional changes as
composition
and methods reducing post traumatic cognitive
a result of aging. or other diseases associated with aging.
25 dysfunction.
have not generally been agreed upon.
Several mechanisms for the generation of oxidized mate
SUMMARY OF THE INVENTION
rial in the brain have been proposed. In particular. transition
metals. especially iron and copper. have been suggested as
Compositions containing as the active ingredient a spin
mediating aspects of this oxidation. A marked reduction in
30 trapping reagent. preferably ot-phenyl butyl nitrone (PBN).
certain neurotransmitter receptor systems has been associ
or spin-trapping derivatives thereof. in a suitable pharma
ated with increased oxidation of proteins. For example.
ceutical carrier for patient. are disclosed for treating or
decreases in muscarinic receptors and other cholinergic
systems have been characterized as they relate to alterations
in functions in Alzheimers disease. It has also been hypoth

esized that aging is associated with multiple minor periods

35

preventing symptoms associated with aging or other condi
tions associated with oxidative tissue damage. The preferred
PBN compositions have the following general formula:

of ischemia (multi-infarct conditions or transient ischemia
attacks) which. over a period of time. may give rise to the

H

production of oxidized protein.

O‘
C=N+

Changes associated with ischemic brain disease have been
proposed to be the result of alterations in calcium
disposition. increase in excitoxic neurotransmitter release.
production of free radicals and the attendant acidosis that

X

Y

wherein:

results in an increase in the loosely related metals in the cell
that are catalytic for the generation of oxygen free radicals.
These changes are largely limited to neuronal elements.
Reactive glia have been demonstrated. however. they are

X is phenyl or

(0R)n

mostly associated with postneuronal damage.
The treatment of age related dementias have been largely
limited by the inability to develop an appropriate model for
the study of this condition. This is due to the fact that aging

50

wherein R is H.

is a very complicated condition which is di?icult to model.

especially with the lack of speci?c information associated
with the functional and biochemical basis of human age
related dementias. The use of animal models has largely
depended upon model systems used in brain studies. where

55

the brains are not truly senescent. or the use of senescent

animals. with little understanding of the origin of the senes
cence or. in some cases. the inability to demonstrate truly

and n is a whole integer from 1 to 5; or

functional senescence.

The demonstration in a variety of systems. both neural
and nonneural. that there is an age related enhancement of

the level of oxidized protein in tissue gives rise to the
possibility that age related dysfunctions in the central ner
vous system may be associated with the build-up of oxidized 65
proteins and oxidized macromolecules within neurons
throughout the central nervous system. The hypothesis is

Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or

5.681.965
4
(FIG. 3C) over days following termination of twice daily
dosing with 10 mg PBN/kg body weight. FIG. 3A represents
the level of carbonyl in the soluble protein obtained from

OW

gerbils treated for fourteen days and tested at 1. 3. 7 and 14
days post dosing. FIG. 3B is the time related decrease in

cortical glutamine synthetase (GS) activity after termination
wherein W is
0

o

0

II

II

II

10

of twice daily injections of PBN. FIG. 3C demonstrates the
time related decrease in alkaline protease activity following
termination of twice daily injections of PBN. Each histo
gram is the meanistandard error (S.E.) of three subjects at
each of the indicated times. The asterisk and dashed line
indicates the old gerbil. untreated control values for each of

and
Z is a C1 to C5 straight or branched alkyl group.
Other spin-trapping agents can also be used. such as

the measures.

FIG. 4A. 4B and 4C are graphs comparing changes in

5.5-dimethyl pyrroline N-oxide-(DMPO)-or ot-(4-pyridyl

protein carbonyl (pnol/mg protein) (FIG. 4A). glutamine

l-oxide)-N-ter1-butylnitrone (POBN). and other spin
trapping derivatives thereof.

synthetase (FIG. 4B). and protease activity (% control)
(FIG. 4C) over days following termination of twice daily
dosing with 32 mg PBN/kg body weight. FIG. 4A represents

In the preferred embodiment. the compositions are admin
istered one to two times daily by oral administration. at a

the level of carbonyl in the soluble protein obtained from
gerbils treated for fom’teen days and tested at 1. 3. 7 and 14
days post dosing. FIG. 4B is the time related decrease in

dosage equivalent to between one and ten milligrams PBN/

70 kg of human body weight. Studies in animals demon
strate that administration of compound for a two week

cortical glutamine synthetase (GS) activity after termination

period reduces the level of oxidized brain enzymes to

of twice daily injections of PBN. FIG. 4C demonstrates the

normal and restores memory to the same level as tested in 25
time related decrease in alkaline protease activity following

young control animals. A signi?cant reduction in oxidized

termination of twice daily injections of PBN. Each histo

proteins and memory recovery is observed as early as seven
days after initiation of treatment; levels are still comparable
to young controls one to three days following cessation of

treatment. and partially reduced at seven days following

30

gram is the meaniSE. of three subjects at each of the
indicated times. The asterisk and dashed line indicates the
old gerbil. untreated control values for each of the measures.

FIG. 5 is a graph of the eight arm radial arm maze

cessation of treatment.
These compositions and methods are useful in the treat

ment of age-related disorders. pro-surgical and/or pro
anesthetic preparation or administration of chemotherapeu
tic agents. and in treatment of disorders or trauma of the 35

brain. cardiovascular system. lymphatic system. and.
potentially. in the treatment of some viral disorders charac
terized by oxidation of host proteins in cells infected by the

performance of young or old gerbils treated with either
saline or PBN. Gerbils were placed into the central com
partment of ?re maze with the barrier in place to limit
exploration. After the barrier was removed. the number of
arms re-entered and the total elapsed time before all eight
arms were entered was recorded. Each histogram represents
the meaniof 18 gerbils. The animals were administered

PBN twice daily (either 10 or 32 mg PBN/kg body weight)

virus.

for seven days and tested at the end of seven days of dosing.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph of the alkaline protease activity from
gerbil cortex (% of young. three to four month old gerbil
cortex) for young gerbils (age three to four months). old
gerbils (retired breeders of twelve to ?fteen months of age).

DETAILED DESCRIPTION OF THE
INVENTION
45

old gerbils that received twice daily injections of 0.1 ml
saline/kg body weight. and old gerbils that received twice
daily injections of 10 mg PBN in saline/kg body weight for
two weeks. Protease activity was determined using oxidized
protein extracted from young gerbil cerebral cortex.

FIG. 2A and FIG. 2B are graphs comparing protein

carbonyl activity (pmollmg protein) (FIG. 2A) and
glutamine synthetase activity (FIG. 2B) in the cerebral
cortex (neocortex) of young adult and old gerbils over days
of administration of 32 mg PBN/kg administered twice a day
for one. three. seven or fourteen days. At the end of each of
the days indicated. animals were decapitated and cerebral

cortex removed and rapidly frozen in liquid nitrogen. Pro
tein carbonyl content was determined using the DNPH
procedure. The results demonstrate the reduction in oxida
tive damage to proteins and the loss of enzyme activity in
gerbil cerebral cortex as a result of twice daily administra

tion of 32 mg PEN/kg (i.p.). Each histogram is the mean of

three subjects.
FIG. 3A. 3B and 3C are graphs comparing changes in

protein carbonyl (pnol/mg protein) (FIG. 3A). glutamine
synthetase (FIG. 3B). and protease activity (% control)

It has now been discovered that. further to the methods

using PBN for the treatment and prevention of ischemic
damage described and claimed in US. Ser. No. 07/422651
?led Oct. 17. 1989. now Reissue US. Pat. No. 35.112.
spin-trapping agents are useful in preventing or treating
SO

symptoms associated with aging. trauma. drug administra
tion and surgery. especially of the brain. As used herein. a
free radical scavenger or spin-trap reagent is a molecule that
will form a stable complex with free radical. A free radical
carbon trap is a molecule in which the free radical is

55 localized on a carbon atom or a nitrogen atom. As a result

of this chemical bond formation. the free radical is no longer
damaging to the cell. In combination with a pharmaceutical
vehicle suitable for administration to a patient. preferably by
oral administration. these compounds are useful in prevent
ing or reversing symptoms associated with aging. for
example. increased levels of oxidized proteins. decreased

enzymatic activity. and spatial and short term memory.
Currently. thm'e are no effective. non-toxic treatments for

aging. Elfectiveness has been demonstrated in animals after
65 as few as seven days of administration. Effectiveness con

tinues for at least one week after administration. Values

return to pretreatment levels after two weeks.

5.681965
5

6

Useful Spin-trapping Compounds

Other Spin-trapping Reagents

PBN and Derivatives Thereof

Other spin-trapping agents can also be used. such as

The preferred spin-trapping compounds are ot-phenyl

5.5-dimethyl pyrroline N-oxide (DMPO) or (1-(4-pyridy1

t-butyl nitrone (PBN). and derivatives thereof. PBN has no
measurable effect on normal or uninjured cells. PBN is the

preferred compound at this time. although a number of
derivatives are also useful. including hydroxy derivatives.
especially 2-. 3- or 4-hydroxy PBN and mono-. di- and

l-oxide)-N-tert-butylnitrone (POBN). and spin-trapping
5

derivatives thereof. Derivatives are made using standard

techniques. for example. for substitution of the methyl
groups. The general formula for DMPO is:

trihydroxy tert-butyl nitrone; esters. especially esters which
release 2-. 3. or 4-hydroxyphenyl t-butyl nitrone such as the

acetoxy derivative. 2-. 3-. or 4-carboxyphenyl t-butyl
nitrone. such as the ethyl derivative. or phenyl hydroxybutyl
nitrone. such as the acetoxy derivative; alkoxyl derivatives.
especially alkoxyl derivatives which release 2-, or
4-hydroxyphenyl t-butyl nitrone. such as the methyl deriva
tive; and acetamide derivatives. especially acetamide deriva
tives which release 2-. or 4 aminophenyl t-butyl nitrone.
such as the acetyl derivative; diphenyl nitrone (PPN) and the
analogous diphenyl nitrone derivatives. As used herein.
“PBN" refers to both phenyl t-butyl nitrone and derivatives
thereof. unless otherwise stated.
The general formula for PBN and useful derivatives
thereof is:
H

.70

10

B l
0

wherein A and B are independently CH3. CH2OH.
CH2OW. or
20

(owln

o

25
C=N+
X

n is an integer from 1 to 5
wherein W is

Y

wherein:
X is phenyl or

30

o

o

0

II

II

II

(0R)n
35

and

Z is a C1 to C5 straight or branched alkyl group.
The general formula for POBN is:

wherein R is H

0

/
and n is a whole integer from 1 to 5; or

45

s \

l
N

\L
Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or

wherein
Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or

ow

OW

wherein
0

o

0

II

II

II

—NH—C—Z, C-CHg, 0-02, or Z;
65

and
Z is a C1 to C5 straight or branched alkyl group.

5,681,965
8
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Treatment of Neurodegenerative Disorders
Several neurodegenerative conditions are most appropri

and

S=H. (0K)". wherein R is H.

ately treated by compounds that interfere with protein oxi
dation. Alzheimer’s disease has been associated with the
accumulation of abnormal oxidized proteins or the produc

n is a whole number from 1 to 4. or
10

tion of abnormal proteins in areas that are pathologically
a?ected. In addition. age related enhancement in protein
oxidation occurs in all cells in the aged individual. PBN and
derivatives thereof have been demonstrated to be useful in
the reduction in protein oxidation and in the increase in the

activity of critical enzymes within the brain of aged animals.
Since this is a fundamental change in oxidative state. it is

likely that PBN and other related compounds would be
useful when given chronically to individuals who are in the

early phases. or possibly in the late phases. of Alzheimer’s
disease. In addition. multi-infarct dementias should be treat

able with these compounds. since they also deal with
ischemia reperfusion oxidation issues.
Senile dementia has not been directly evaluated for
ischemia reperfusion etiology or protein oxidation. however.
it is likely that senile dementia would also be treatable with
these compounds. This is based on the hypothesis that
advanced age is associated with increased production of
oxidized protein. In progeria. a unique condition in which
aging is accelerated. Stadtrnan and colleagues at the NIH

Z is a C1 to Cs straight or branched alkyl group.
Indications ‘That the Compositions are Useful in Treating
The free-radical scavenger compositions are useful in
treating a variety of dysfunctions or disorders characterized
by oxidized proteins in the tissues or cells. Oxidation of
cytosolic protein has been demonstrated to occur in a wide

variety of pathological conditions. Accordingly. compounds
which have as their fundamental mechanism of action the

interference of production of oxidized protein should be

25

have demonstrated that there is a marked increase in the

tered to a patient to reverse the damage occurring as a
function of age. Preliminary results indicate that there is a

base-level of oxidized protein even in young adult subjects
with progeria. as reported by Oliver. et al.. J. BioL Chem.
262. 5488-5491 (1987) and Starke-Reed and Oliver. Arch.
Biochem. Biophys. 275. 559-567 (1989). While this is arare
condition it should also be treatable with these composi
tions.
Another condition which is likely to be associated with

net increase in the oxidation of proteins and the accumula
tion of oxidized material in the brain. The development of

is the diabetic peripheral neuropathies and vascular change.

useful in the treatment of a wide variety of diseases having
what appears at ?rst glance to be widely dissimilar
etiologies. because the fundamental cause of the condition is
oxidation of protein or nucleic acids.
In one embodiment. the spin-napping agent is adminis

senil plaque is also routinely observed in aged patients.

oxidative damage arising from microcirculatory di?iculties
35

These are tragic conditions in which amputation is eventu
ally necessary in order to save the patient. While these
compounds are not likely to improve vascular ?ow they are
likely to reduce the impact of transient changes in vascular
?ow which result in oxidation and damage to the peripheral

40

nerves and also in damage to the skeletal muscle which is
often associated with the condition called exercise induced
or intermittent claudication. If the retinopathy associated
with diabetes is also an ischemia reperfusion microcircula

Other disorders are those resulting from trauma. such as
a blow to the head. or from drug treatment. for example.
administration of anesthesia or drug abuse. or even as a

result of some types of viral infections.
It has now been determined that the level of oxidized

brain protein appears to be inversely related to performance
in a short term memory task and directly related to risk of

stroke-induced damage and behavioral change. Increased

tion problem. then the spin~trapping compounds will be

cellular oxidation may result in one or more of the follow

ing: (a) oxidative damage to cellular proteins could cause a
change in the regulation of ion channels. there could be a

45

Pre-surgical Preparation

change in the rate and e?iciency of signal translation and
membrane depolarization. significant changes in energy

Since the status of the cell and its survival in a hypoxic or

anoxic environment is dependent upon the ability of the cell

?uxes may occur and compromise selective function. the
?delity of RNA transcription may be altered due to oxidative
damage to DNA. RNA translation may be affected either by

to compartrnentalize metals and handle oxygen in a useful
manner. in contrast to peroxidation. it is expected that these
compounds will be useful as presurgical preparatory medi
cation to reduce the carbonyl load and improve the enzyme
status of the patient prior to elective surgery. These com

oxidation of the RNA or regulatory macromolecules. or the

rate of protein degradation may be altered.
Any of these changes could negatively impact on the
acquisition consolidation and retrieval of information. even

useful in treating the retinal damage which occurs very

frequently in diabetic patients.

55

pounds would also help the cells of the body achieve a

by interference with a single step in the learning and

higher level of enzymatic function. shorten the recuperative

memory process. It is possible that oxidation of cells in a

phase. and reduce the likelihood of any interoperative com

particular brain region could result in acquisition de?cits.

plications associated with changes in rnicrocirculation.
Treatment of Viral Infections and In?ammatory Disorders
Retroviruses selectively infect certain types of cells. such

whereas oxidation of a diiferent region could result in output

de?ciency. Considering the number of devastating neurode
generative diseases. including Alzheimer’s disease. this

as lymphocytes. An example of a retrovirus that has been the

treatment could potentially be a tremendous help to people
with these disorders.
Examples of other disorders that can be treated with these

?ciency virus (HIV). which causes Acquired Immunode?
ciency Syndrome (AIDS). No means for prevention of

compositions include peripheral neuropathy of diabetes.
exercise induced muscle damage and pain. and enhancement
of cellular response to hormonal signals.

subject of much research activity is the human immunode
65

infection has been found. although there have been numer
ous attempts to find a treatment Since activation of lym

phocytes is associated with the oxidation of protein and

5,681,965
10
activation of lymphocytes is required prior to release of
newly formed viruses. it is expected that administration of
these compositions will inhibit infection and replication of
lymphocytes by the viruses. The activation of the T4

or may be divided into a number of smaller doses to be

administered at varying intervals of time. Other methods of
administration can also be used. including subcutaneous.
intravenous. and intraperitoneal administration. The concen

lymphocyte is associated with a cascade of biochemical
intracellular changes. one of which is the production of
oxidized protein. If PBN related compounds can block
protein oxidation in the abnormal process then it is possible
that PBN or other spin-trappin compounds could in fact

tration of active compound in the drug composition Will
depend on absorption. inactivation. and excretion rates of
the drug as well as other factors known to those skilled in the
art. The effective dosage may also be determined based on
that amount required to prevent or reverse predisposition of

interfere with the process of viral replication and/or dissemi
nation of the virus from the host cell (T-4 lymphocyte).
thereby acting as a vimstatic agent by preventing the T-4
lymphocyte from releasing the newly formed viruses. This

the cells to damage resulting from depletion of ATP (as
demonstrated by in vivo NMR) and damage from free
radical generation. It is to be noted that dosage values will
also vary with the condition of the patient being treated. It
is to be further understood that for any particular subject.

would be analogous to the use of isoniazid (INH) in the
treatment of tuberculosis. At low doses INH is a tubercula
static in that it reduced the infectivity and spread of the

speci?c dosage regimens should be adjusted over time
according to the individual need and the professional judg

tuberculosis. thereby eifectively protecting the patient from

ment of the person administering or supervising the admin
istration of the compositions. and that the concentration

pulmonary damage.
It is important to note that the eifects of the spin-trapping
compounds occur in animals that have a base-level of

20

ranges set forth herein are exemplary only and are not
intended to limit the scope or practice of the claimed

composition.

carbonyl formation which appears to be necessary for post
translational processes. Old animals have a signi?cantly
elevated level of carbonyl protein which is associated with
decreased enzymatic function relative to young control

A preferred mode of administration of the active com
pound is in a form for oral delivery. Oral compositions will
generally include an inert diluent or an edible carrier.

animals. When young control animals are given the exact 25 Preferred pharmaceutical carriers for intravenous adminis
same dosage regimen. there is no signi?cant change in
tration are saline or phosphate buifered saline at physiologi

enzyme activity nor is there signi?cant change in protein
carbonyl. Thus the PBN and related spin-trapping com
pounds are not likely to interfere with fundamental pro
cesses that are necessary for the normal cellular function.

cal pH. Since PBN degrades at pH less than approximately
3 to 4. it is preferred to administer the PBN at a pH of 4 or
higher. or in combination with food. a buffering agent. or in
30

an enteric coating. For oral delivery. the PBN may be

In conclusion. a number of clinical conditions appear to
have as their fundamental cause oxidation of cellular protein

enclosed in capsules. compressed into tablets.
microencapsulated. entrapped in liposomes. in solution or

and enzymatic damage. Spin-trapping compounds are eifec

suspension. alone or in combination with a substrate immo
bilizing material such as starch or poorly absorbable salts

tive in animal models in reducing the protein oxidation and
improving enzymatic function. This occurs in preparations
in which the abnormal oxidized protein is modi?ed and
protected but the normal post translational oxidation is

35

allowed to occur. This would suggest that PBN does not

interfere with the normal necessary oxidation of proteins

following synthesis.
E?iective Dosages of PBN
Exemplary dosages of PBN range from 0.1 to 10 mg/kg
of body weight in animals. The eifective dosage of PBN in
humans is expected to be between approximately 1 and 10
mg/70 kg body weight. Toxicity tests have demonstrated that
the compound is completely innocuous. with such low

sucrose or saccharin; or a ?avoring agent such as
45

from either the trauma or anesthesia.

modify the physical form of the dosage unit. for example.
50

coatings of sugar. shellac. or other enteric agents.
The present invention will be further understood with

reference to the following non-limiting examples demon
strating methods for determining effectiveness of PBN
administration for treatment or prevention and/or reversal of
55

Since the trapping of endogenous free radicals is speci?c
for only those cells that have been exposed to the conditions
that result in the production of free radicals. the traps have

symptoms associated with aging.
Example 1
Determination of Brain Enzyme Levels in Old Versus
Young Gerbils Treated with PBN
A correlations between the duration of ischemia and either
the change in spontaneous behavior or the level of oxidized
brain protein has previously been demonstrated in gerbils.

little or no effect on normal cells. The bene?cial effects

occur only in injured cells. and do not require the presence

of speci?c receptors. speci?c enzymes. and/or speci?c cell
types
Methods of Administration of PBN

The PBN is preferably administered systemically. most
preferably orally. since this is the most rapid and e?icient

peppermint. methyl salicylate. or orange ?avoring. When
the dosage unit form is a capsule. it can contain. in addition
to material of the above type. a liquid carrier. In addition.
dosage unit forms can contain various other materials which

toxicity that it was not possible to determine an LDSQ.
In the preferred application. the PBN is administered to a

patient su?’ering from memory loss or other symptoms
frequently associated with aging. Optimum results are gen
erally observed after two weeks of daily or twice daily oral
administration. The compositions can also be effectively
administered prior to. during or shortly after surgery. and
prevent or decrease the extent of cellular damage resulting

such as immodiurn. Pharmaceutically compatible binding
agents can be included as part of the composition. The
tablets or capsules may contain. for example. any of the
following ingredients. or compounds of a similar nature: a
binder such as microcrystalline cellulose. gum tragacanth or
gelatin; an excipient such as starch or lactose. a disintegrat
ing agent such as alginic acid. Primogel®. or corn starch; a
lubricant such as magnesium stearate or Sterotes; a glidant
such as colloidal silicon dioxide; a sweetening agent such as

Many other psychiatric and neurological conditions have

means for delivering the active compound to the site of free

been proposed to be the result of oxidation. Among these
conditions. cellular aging has been associated with oxygen
radicals and the accumulation of proteins. The level of

radical generation. The PBN may be administered at once.

oxidized protein. glutamine synthetase activity. brain pro
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tease activity and radial arm maze performance in young
adult and retired breeder gerbils have now been compared
and demonstrate that there is a direct relationship between

dictable rate and that there are mechanisms existent within
the cells of the brain which can remove this oxidized protein

if the process is interrupted.

the age of the subject and the level of oxidized brain protein.
as measured using a protein carbonyl assay. Increased levels
of protein carbonyl were associated with decreased
glutamine synthetase activity and decreased alkaline pro

FIG. 2B compares the levels of glutamine synthetase (gs)
in young and old animals and evaluates the effects of daily
administration of PBN on the speci?c activity of the
enzyme. This particular enzymatic marker has been selected
because it is a highly sensitive protein to oxidation and
because it is a metalloprotein that has bound to it metal
which may participate in the generation of free radicals if the
metal is dissociated with its binding site. Glutarnine syn

tease activity. In contrast. there was no change in acid

protease activity of retired breeders, compared to young
adult gm’bils. Consistent with the age-related increase in
protein oxidation and enzyme damage. retired gerbils made
signi?cantly greater numbers of errors in a test of short-term

thetase activity has been used by Stadman and colleagues
(Oliver. et al.. Proc. Natl. Acad. Scie. USA. 87. 5144-5147

memory. compared to young adult gerbils. These studies
demonstrate that the functional de?cits that occur as a result

of aging may be associated with increased protein oxidation

15

and decreased brain enzyme activities.
This system has been used to demonstrate the effective
ness of PBN in restoring young brain enzyme levels and
short term memory to old animals. The results are shown in

FIGS. 1 through 5. as follows. Young gerbils were obtained
from Tumblebrook Farms. West Brook?eld. Mass. weigh
ing 50-60 grams and age three to four months. Control
gerbils were given saline. Animals were killed by decapita
tion and their brains removed for analysis.
FIG. 1A is a graph of the percent alkaline protease in

young (three to four month old) gerbils. old (twelve to
?fteen month old retired breeder) gerbils. old gerbils admin
istered 0.1 ml saline twice daily (b.i.d.). and old gerbils
administered 10 mg PBN/kg body weight b.i.d. for fourteen

days.

20
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As shown in FIG. 2B. the level of glutamine synthetase is
lower in old gerbils (1.2) than in young adult gerbils (2.1).
This is consistent with previous studies in which increases in

the level of the carbonyl protein (oxidized protein in cells)
is associated with a decrease in glutamine synthetase activ

ity. In particular. if the glutamine synthetase enzyme is
puri?ed and the carbonyl content of that enzyme is
25

evaluated. there is a marked increase in the level of oxidized

protein in the presence of lowered glutamine synthetase
activity. As also demonstrated in FIG. 2B. repeated admin
istration of PBN in young gerbils had no effect on glutamine

synthetase activity. providing further evidence that the level
30

of carbonyl is associated with normal function and chronic
administration of PBN has no effect on either the level of
carbonyl or on the marker enzyme activity. In contrast to the

The results demonstrate that PBN is effective in restoring
alkaline protease levels in old animals to those levels present
in young animals.

FIG. 2A is a graph of the changes in protein oxidation
from brains of young and senescent gerbils. plotting nmol

(July 1990)) as a marker enzyme for alterations following
protein oxidation.

young gerbils. old gerbils given daily injections of PBN
show a time related increase in glutamine synthetase activity
35

protein carbonyl/mg protein versus days of treatment with
PBN. The gerbils were given twice daily injections of 32

that parallels the reduction in protein carbonyl content.
indicating that the reduction in oxidized protein burden of
cells is associated with a recovery of the enzymatic activity

mg/kg PBN for fourteen days. Animals were killed at one.
three. seven and fourteen days and protein carbonyl levels
determined.
As can be seen in the ?gure. there is no change in the level

to the normal level seen in young adult gerbils.

of oxidized protein of young gerbils treated for up to 14 days
with PBN. This indicates that the level of oxidized protein

enzymatic activity but does not result in an activation of
enzyme activity that exceeds the normal values.

is likely to be a natural and necessary post translational

It is important to note that there is no increase in enzy

matic activity above that seen in young adult gerbils. Thus
the treatment with PBN reverses the e?’ect of aging on

45

effect. for example. if after synthesis of the protein. the
protein is activated by a modi?cation involving carbonyl

Example 2

oxidation. In contrast to the carbonyl level seen in young

Determination of Residual Effect of PBN on Reduction of

animals. control aged animals (15‘ months of age) have a

Brain Enzyme Levels

marked increase of carbonyl content. This increased carbo
nyl content is responsive to treatment with PBN. Multiple
days of treatment with PBN results in a progressive reduc
tion in the level of protein carbonyl to the level seen in
young animals.

The level of protein carbonyl reduction (oxidized protein
burden of neurons in the brain) is only to the level of the

normal young gerbil brain. Neither the levels in the young
gerbil brain nor the levels in the senescent gerbil brain can
be ftn'ther reduced beyond this level. This observation
supports the hypothesis that there is a necessary level of
oxidation that occurs in cells in normal animals. which is
required for cells to have “normal function”. and that control

As shown in FIGS. 3A. 3B. and 3C. as compared with
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FIGS. 4A. 4B. and 4C. administration of 10 mg PBN/kg is
as effective as administration of 32 mg PBn/kg body weight
in restoring young enzyme levels. The appropriate dosages
and full range of effective dosages for other species of
animals can be determined using a similar methodology.

The time related changes in protein oxidation and enzyme

activity following termination of twice daily dosing with
either 10 mg PEN/kg (FIGS. 3A. B. and C) or 32 mg
PBN/kg (FIGS. 4A. B. and C) are also shown by these
?gures. The results demonstrate that the eifect of the PBN is
unaltered one to three days after termination of treatment

twice daily with the PBN. although the PBN itself has a
aged animals (15 months of age) have a marked increase of
half-life of three hours. At seven days. the enzyme levels are
carbonyl content. This increased carbonyl content is respon
sive to treatment with PBN. The ability of PBN to reduce the 65 altered by approximately 50%. At fourteen days. the oxi
dized enzymes have returned to approximately their pre
protein carbonyl load of cells also indicates that this is an
active oxidation process which occurs at a regular or pre

treatment levels.

5,681,965
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Example 3

-continued
0.

Demonstration of Correlation Between Elfect of PBN on

Brain Enzymes and Memory
FIG. 5 demonstrates that there is a functional counterpart
to such treatment. Young and old gerbils were tested in a
radial arm maze test for spacial and short term memory.
Animals were placed in the central hub of a eight armed
Y is a tert-butyl group that can be hydroxylated or
radial maze and given access to explore all eight arms of the 10
acetylated
radial arm maze. When the animal completed the test of
on one or more positions; phenyl; or
exploring each of the eight arms. the animal was removed
from the maze. The number of times that the animals
OW
O
0
reentered arms that had been previously entered was counted

II

as an error. Under ideal conditions animals will enter each
one of the eight arms but not reenter any of the arms. In

II

II

; whereWisNH-C-Z. C-CHg, C-OZ, or Z;

many cases young adult gerbils (young) entered each of the
arms without reenten'ng any of the arms. The time required
to enter all eight arms was also recorded but did not appear

and

to determine the e?iciency of the short term memory task. As
can be seen in FIG. 5. young gerbils made an average of 2.83
errors during the test session. In contrast. old gerbils made
an average of 6.82 errors. which is a highly signi?cant

wherein Z is a C1 to Cs straight or branched alkyl group.
2. The compound of claim 1 wherein X is

difference between the two groups.

Young adult gerbils exposed to a period of transient
ischemia. which is also an oxidizing process. make a sub
stantial number of errors with an average value of 15 errors

in such a test session. During the post ischemic period. there
is a marked build up of carbonyl protein and reduction in
glutamine synthetase activity similar to that which is seen in
aging.
Treatment of gerbils for seven days results in a marked
alteration in the number of errors seen with old gerbils.

30

3. The compound of claim 2 wherein Z is methyl.
4. The compound of claim 3 wherein Y is a tert-butyl
group.
5. The compound of claim 1 wherein X is

35
o

Young gerbils given PBN for seven days were not signi?
cantly di?erent from control gerbils whereas the old gerbils

—CH=N+

given PBN for seven days showed a marked reduction in the
number of errors and returned to the range of performance
seen with control young gerbils. Thus. there is a functional
counterpart to the biochemical changes that are seen in that

Y

6. The compound of claim 1 wherein Y is a tert-butyl
group that can be hydroxylated or acetylated.

reduction in protein carbonyl and the increase in glutamine
synthetase activity following chronic PBN treatment. This

7. The compound of claim 1 wherein Y is phenyl.

functional counterpart is demonstrated by the number of

8. The compound of claim 1 wherein Y is

errors seen in a short term spacial memory task. the radial
OW

arm maze. It should be noted that the radial arm maze test

does not require any food reinforcement or any other reward
associated with the test. Naive animals are placed into the
radial arm maze. are tested once and these dijferences are
reliable on retest.

9. A compound of the formula:

Modi?cations and variations of the method and compo
sition for the treatment of aging will be obvious to those

0

sldlled in the art from the foregoing detailed description.

ll

Such modifications and variations are intended to come

CH3—C—NH

within the scope of the appended claims.
We claim:

1. A compound of the formula:

10. A compound of the formula:
a

\
/
X
wherein:
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wherein:

5,681,965
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16

X is

17. A compound of the formula:

(OR).-

IF
5

HC=N—Y

/

wherein R is H.

S

o

0-

n

Z—C—,

or

z;

or

I

\

1°

N

\l,O

—CH=N+

Y

15 wherein
'

'

and n 15 a Whole Integer from

1 t

;

.

o 5 or

Y 1s a tert-butyl group that can be hydroxylated or

O

acetylated on one or more positions; phenyl; or

II
NH-C-ZI

ow
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0

0

II

II

; where W is N'H-C —Z-, —-C—Cl-[3,

Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; or

o
||
25

0W

H
;

—C—0Z, or Z;

H

where WisNH-C-Z,

or

C-OZ,

and

3D

S=(OR),,. wherein R is H.
0

and

0

H
Z-C—, Z, or —CH=N+

wherein Z is a C1 to C5 straight or branched alkyl group. 35

and

Y

11. The compound of claim 10 wherein X is
Y is as de?ned above.
NH_C_ZI

n is a whole number from 1 to 4. or
40

0

ll
Nl-l-C —Z;

12. The compound of claim 11 wherein Z is methyl.
13. The compound of claim 10 wherein X is
45

wk)»

and

Z is a C1 to C5 straight or branched alkyl group.
18. The compound of claim 17 wherein Y is a tert-butyl
50 group that can be hydroxylated or acetylated.
~

-

-

19. The compound of claim 17 wherein Y is phenyl.
20. The compound of claim 17 wherein Y is

14. The c°mp°und °f c1mm 10 Whcm“ X ‘s
0

ow

—CH=N+
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Y

15. The compound of claim 10 wherein Y is a tert-butyl
group that can be hydroxylated or acetylated

21_ A compound of the formula:
60

16. The compound of claim 10 wherein Y is

71-;
A

ow

” i
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0

5 ,68 l .965
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18
and
Z is a C1 to C5 straight or branched alkyl group.
22. The compound of claim 21 wherein at least one of A
andBis

wherein A and B are independently CHZOW. or

(0W),
7

5

(CW),
and
n is an integer from 1 to 5.
wherein W is

10

23. The compound of claim 21 wherein at least one of A

and B is CHZOW.

